EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial

Michael A Cilento iD, Hui-Ming Lin iD, Nicole Yeung, Rachel M N Kim, Neil Portman, Martin R Stockler iD, Andrew J Martin, Vinod Subhash, Sonia Yip, Lisa M Butler iD, Ian C Marschner, Peter J Meikle und 4 weitere

The Prostate · 2026

DOI: 10.1002/pros.70245 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Prostate, 2026. Verfasst von Michael A Cilento und 15 weiteren Autor:innen. Beteiligte Einrichtung: South Australian Immunogenomics Cancer Institute, Adelaide University, Adelaide, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Insulin-Like Growth Factor I, Phenylthiohydantoin, Insulin-Like Growth Factor Binding Protein 1. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Australia, Prostate Cancer Foundation of Australia, Australian Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and included participants who also received docetaxel as standard of care. The aim of this study was to validate the association between levels of circulating IGF‐1 and IGFBP1 and survival of ENZAMET participants.

Methods

IGF‐1 and IGFBP1 levels were measured in baseline plasma from 845 ENZAMET participants, and associations with clinical progression‐free survival (cPFS) and overall survival (OS) were assessed as a post‐hoc analysis.

Results

A high baseline plasma ratio of IGF‐1:IGFBP1 (upper two tertiles) was associated with improved OS (HR 0.75, p 0.008) and improved cPFS (HR 0.82, p 0.034) compared to the lowest tertile. IGF‐1:IGFBP1 was not predictive of enzalutamide or docetaxel benefit (no significant interaction with treatment arm or docetaxel use). In participants in the enzalutamide arm, IGF‐1:IGFBP1 was an independent predictor for OS and cPFS in bivariable analysis with docetaxel use. The rate of high volume disease was similar in patients with lower IGF‐1:IGFBP1 ratio and those with high ratio (~50%).

Conclusions

This analysis demonstrated a consistent association of improved prognosis with high IGF‐1:IGFBP1 in mHSPC, but did not identify which participants benefited from docetaxel when treated with enzalutamide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsInsulin-Like Growth Factor IPhenylthiohydantoinInsulin-Like Growth Factor Binding Protein 1HumansMaleNitrilesDocetaxelBenzamidesAgedAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsMiddle AgedNeoplasm MetastasisPrognosis

Stichwörter der Autor:innen

biomarkerschemotherapyinsulin‐like growth factorprostate cancer

Substanzen

Insulin-Like Growth Factor INitrilesPhenylthiohydantoinInsulin-Like Growth Factor Binding Protein 1DocetaxelenzalutamideBenzamidesIGFBP1 protein, humanAndrogen AntagonistsIGF1 protein, human

Autor:innen und Institutionen

  • South Australian Immunogenomics Cancer Institute, Adelaide University, Adelaide, Australia.
  • Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia.
  • Australia and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, Australia.
  • Garvan Institute of Medical Research, Sydney, Australia.
  • School of Clinical Medicine, University of New South Wales, Sydney, Australia.
  • NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.

ORCID-Profile: Michael A Cilento, Hui-Ming Lin, Martin R Stockler, Lisa M Butler, Arun A Azad, Ian D Davis, Lisa G Horvath, Christopher J Sweeney

Förderung

  • Cancer Australia
  • Prostate Cancer Foundation of Australia
  • Australian Government
  • Research Training Program Scholarship
  • Tour de Cure
  • Astellas Pharma
  • Supplier of enzalutamide and costs of carrying out ENZAMET
  • National Health and Medical Research Council

Zitieren

APA

Cilento, M. A., Lin, H. M., Yeung, N., Kim, R. M. N., Portman, N., Stockler, M. R., Martin, A. J., Subhash, V., Yip, S., Butler, L. M., Marschner, I. C., Meikle, P. J., Azad, A. A., Davis, I. D., Horvath, L. G., & Sweeney, C. J. (2026). Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial. The Prostate. https://doi.org/10.1002/pros.70245

Vancouver

Cilento MA, Lin HM, Yeung N, Kim RMN, Portman N, Stockler MR, et al. Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial. The Prostate. 2026. doi:10.1002/pros.70245

BibTeX
@article{Cilento2026,
  author = {Cilento, Michael A and Lin, Hui-Ming and Yeung, Nicole and Kim, Rachel M N and Portman, Neil and Stockler, Martin R and Martin, Andrew J and Subhash, Vinod and Yip, Sonia and Butler, Lisa M and Marschner, Ian C and Meikle, Peter J and Azad, Arun A and Davis, Ian D and Horvath, Lisa G and Sweeney, Christopher J},
  title = {Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70245}
}
Kostenlos starten →